InSysBio to present posters at ASCPT 2024 Annual Meeting

March 6, 2024

InSysBio announces its participation in the ASCPT 2024 Annual Meeting which is to be held March 27-29, at the Broadmoor in Colorado Springs, CO. Tatiana Karelina, Head of Neurodegenerative Diseases modeling team, and Vladislav Leonov, CYTOCON DB team, will present 4 posters by InSysBio in frames of the Meeting, namely:

Thursday, March 28, 2024 5:00 PM – 6:30 PM MDT:

  • PII-014 "Unraveling IL9 serum distribution patterns: insights from the CYTOCON Database" by Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
  • PII-220 "Response to lymphocyte depleting and lymphocyte modulating therapies in different populations of patients with multiple sclerosis investigated by Quantitative Systems Pharmacology model" by Tatiana Karelina, Maria Myshkina, Oleg Demin. The poster will be denoted by a Top Poster Ribbon
  • PII-221 "Tetravalency impact on bispecific antibody-achieved receptor occupancy and target downregulation: estimation by translational PK/RO model of CTX8371 antibody" by Veronika Musatova, Oleg Demin, Oleg Demin Jr, Dmitry Shchelokov
  • PII-222 "Validation of a Quantitative Systems Pharmacology model for Chronic Hepatitis B" by Galina Lebedeva1, Alexander Stepanov1, Veronika Musatova2, Oleg Demin1, Loveleena Bansal3, Cibele V. Falkenberg3, Valeriu Damian

Affiliation: (1) InSysBio UK, Edinburgh, UK; (2) InSysBio CY, Paphos, Cyprus; (3) GSK, Collegeville, PA, US

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit